These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34883074)

  • 1. Preclinical evaluation of the dual mTORC1/2 inhibitor sapanisertib in combination with cisplatin in nasopharyngeal carcinoma.
    Zhang J; Jiang Y; Yu Y; Li J
    Eur J Pharmacol; 2022 Jan; 915():174688. PubMed ID: 34883074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma.
    Yang F; Qian XJ; Qin W; Deng R; Wu XQ; Qin J; Feng GK; Zhu XF
    PLoS One; 2013; 8(3):e59879. PubMed ID: 23533654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma.
    Wong CH; Loong HH; Hui CW; Lau CP; Hui EP; Ma BB; Chan AT
    Invest New Drugs; 2013 Dec; 31(6):1399-408. PubMed ID: 23975511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
    Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
    Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chloroform extract from Sophora Tonkinensis Gagnep. inhibit proliferation, migration, invasion and promote apoptosis of nasopharyngeal carcinoma cells by silencing the PI3K/AKT/mTOR signaling pathway.
    ShuoWang ; Song Z; Gong X; Ou C; Zhang W; Wang J; Yao C; Qin S; Yan B; Li Q; Wei K; Hou X; Zhou X; Miao J
    J Ethnopharmacol; 2021 May; 271():113879. PubMed ID: 33524509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTOR kinase inhibition reduces tissue factor expression and growth of pancreatic neuroendocrine tumors.
    Lewis CS; Elnakat Thomas H; Orr-Asman MA; Green LC; Boody RE; Matiash K; Karve A; Hisada YM; Davis HW; Qi X; Mercer CA; Lucas FV; Aronow BJ; Mackman N; Versteeg HH; Bogdanov VY
    J Thromb Haemost; 2019 Jan; 17(1):169-182. PubMed ID: 30472780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting nasopharyngeal carcinoma by artesunate through inhibiting Akt/mTOR and inducing oxidative stress.
    Li Q; Ni W; Deng Z; Liu M; She L; Xie Q
    Fundam Clin Pharmacol; 2017 Jun; 31(3):301-310. PubMed ID: 28078787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma.
    Liu T; Sun Q; Li Q; Yang H; Zhang Y; Wang R; Lin X; Xiao D; Yuan Y; Chen L; Wang W
    Mol Cancer Ther; 2015 Feb; 14(2):429-39. PubMed ID: 25504751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines.
    Ma BB; Lui VW; Hui EP; Lau CP; Ho K; Ng MH; Cheng SH; Tsao SW; Chan AT
    Invest New Drugs; 2010 Aug; 28(4):413-20. PubMed ID: 19471857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical efficacy and involvement of mTOR signaling in the mechanism of Orf virus against nasopharyngeal carcinoma cells.
    Huang Y; Gong K; Chen J; Deng H; Weng K; Wu H; Li K; Xiao B; Luo S; Hao W
    Life Sci; 2022 Feb; 291():120297. PubMed ID: 35007565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule inhibitor TW-37 is tolerable and synergistic with chemotherapy in nasopharyngeal carcinoma.
    Lu Y; Huang H; Yang H; Chen D; Wu S; Jiang Z; Wang R
    Cell Cycle; 2017 Jul; 16(14):1376-1383. PubMed ID: 28696828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel Smac mimetic APG-1387 demonstrates potent antitumor activity in nasopharyngeal carcinoma cells by inducing apoptosis.
    Li N; Feng L; Han HQ; Yuan J; Qi XK; Lian YF; Kuang BH; Zhang YC; Deng CC; Zhang HJ; Yao YY; Xu M; He GP; Zhao BC; Gao L; Feng QS; Chen LZ; Yang L; Yang D; Zeng YX
    Cancer Lett; 2016 Oct; 381(1):14-22. PubMed ID: 27424523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity.
    Rubens JA; Wang SZ; Price A; Weingart MF; Allen SJ; Orr BA; Eberhart CG; Raabe EH
    Neuro Oncol; 2017 Oct; 19(10):1361-1371. PubMed ID: 28582547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.
    Slotkin EK; Patwardhan PP; Vasudeva SD; de Stanchina E; Tap WD; Schwartz GK
    Mol Cancer Ther; 2015 Feb; 14(2):395-406. PubMed ID: 25519700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma.
    Miyahara H; Yadavilli S; Natsumeda M; Rubens JA; Rodgers L; Kambhampati M; Taylor IC; Kaur H; Asnaghi L; Eberhart CG; Warren KE; Nazarian J; Raabe EH
    Cancer Lett; 2017 Aug; 400():110-116. PubMed ID: 28450157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
    Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
    Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer effects of brusatol in nasopharyngeal carcinoma through suppression of the Akt/mTOR signaling pathway.
    Guo S; Zhang J; Wei C; Lu Z; Cai R; Pan D; Zhang H; Liang B; Zhang Z
    Cancer Chemother Pharmacol; 2020 Jun; 85(6):1097-1108. PubMed ID: 32449143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined inhibition of RNA polymerase I and mTORC1/2 synergize to combat oral squamous cell carcinoma.
    Shi S; Luo H; Wang L; Li H; Liang Y; Xia J; Wang Z; Cheng B; Huang L; Liao G; Xu B
    Biomed Pharmacother; 2021 Jan; 133():110906. PubMed ID: 33190037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. APLNR is involved in ATRA-induced growth inhibition of nasopharyngeal carcinoma and may suppress EMT through PI3K-Akt-mTOR signaling.
    Liu Y; Liu Q; Chen S; Liu Y; Huang Y; Chen P; Li X; Gao G; Xu K; Fan S; Zeng Z; Xiong W; Tan M; Li G; Zhang W
    FASEB J; 2019 Nov; 33(11):11959-11972. PubMed ID: 31408612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine synergizes with cisplatin to inhibit nasopharyngeal carcinoma cell proliferation and tumor growth.
    He SW; Zhang Y; Chen L; Luo WJ; Li XM; Chen Y; Huang SY; He QM; Yang XJ; Li YQ; Liu N; Zhao Y; Ma J
    FASEB J; 2021 Oct; 35(10):e21885. PubMed ID: 34478585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.